Long-Term Investment Demand for Pharma and Bio IPOs 'Frozen'
Newly Listed Stocks Fall Below IPO Price
Institutional Investors Reluctant to Hold Newly Listed Companies Long-Term
Investor sentiment in the biotechnology initial public offering (IPO) market is rapidly cooling in the second half of the year. With the KOSDAQ market experiencing significant turbulence and share prices of newly listed biotech firms falling below their IPO prices, institutional investors are increasingly reluctant to hold onto newly listed companies over the long term.
According to the investment banking (IB) industry on July 29th, only 28 out of 307 institutional investors participating in the book-building for Ingenia Therapeutics—a company developing antibody drugs for vascular diseases—committed to a lock-up period, making up just 9.1%. Among them, 24 agreed to hold for 15 days, and none committed to a six-month holding period. Based on the number of shares applied for, the lock-up commitment ratio was 2.23%. The IPO price was set at 12,000 won, the lowest end of the hoped-for range of 12,000 to 14,500 won.
A representative from Ingenia stated, "Due to increased market volatility recently, the proportion of lock-up commitments is low in mid- to large-cap stocks and in companies where the IPO price is set at the lower end of the expected range," adding, "We will focus on enhancing corporate and shareholder value through accelerating clinical trials and developing follow-up candidates."
A lock-up commitment indicates that the institution is willing to accept share price volatility and invest in the company's growth potential for a certain period. For drug development companies, where clinical trials and product approval can take several years, the role of long-term capital is even more critical. Despite improvements to the IPO system in the second half of last year that allowed lock-up-committing institutions to receive preferential IPO allocations, the ratio remained in the 2% range. This suggests that the current market is prioritizing IPO share price performance and potential for capital recovery over long-term growth prospects.
The weakened IPO investment sentiment for biotech firms is also being attributed to the poor performance of the KOSDAQ market. As domestic stock market funds have concentrated on major semiconductor stocks, KOSDAQ and biotech shares were sidelined even during rallies. The market correction phase has exacerbated these declines. On July 28th, the KOSDAQ index closed at 705.85, plunging 7.72% from the previous trading day. During the trading session, it fell below the 700 mark for the first time in one year and three months. After reaching 1,229 in April, the index has fallen more than 40% in just three months. In addition, negative factors such as recent failed clinical trials and drug approval delays have fueled caution toward pharmaceutical and biotech stocks.
Until the first half of the year, institutional demand for long-term holding of biotech IPOs was solid. Companies such as Kanaph Therapeutics, iMbioLogics, and Inventhera, which listed on KOSDAQ, all set their IPO prices at the upper end of their hoped-for ranges. Their lock-up commitment ratios based on the number of shares applied for were 76.1%, 76.0%, and 43.1%, respectively. Compared to the average commitment ratio for all 17 newly listed companies in the first half (46.3%), these rates were generally similar or higher. In contrast, the lock-up commitment ratio for HL Genomics, an active pharmaceutical ingredient (API) company that listed on July 24th, was only 1.91%.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Although the IPO market as a whole may gradually recover in the second half of the year based on a pipeline of new offerings, the perceived investment sentiment for biotech companies is expected to remain subdued for the time being. Unless share prices for KOSDAQ and existing newly listed stocks rebound, subsequent biotech IPOs are likely to continue facing conservative evaluations for both IPO prices and lock-up commitments. The distinction between companies with proven achievements—such as solid clinical data or successful technology transfers—and those without will also likely become more pronounced.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.